Neos Therapeutics, Inc. (NASDAQ:NEOS) received a $20.00 price objective from equities researchers at Cantor Fitzgerald in a report released on Wednesday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 92.31% from the stock’s current price.

A number of other research analysts have also recently commented on NEOS. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Wells Fargo & Company set a $14.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 18th. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Royal Bank Of Canada set a $12.00 price target on shares of Neos Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Finally, Cowen and Company restated a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Neos Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.00.

Neos Therapeutics (NASDAQ:NEOS) traded down 1.202% during trading on Wednesday, hitting $10.275. The stock had a trading volume of 243,757 shares. The stock has a 50-day moving average price of $8.74 and a 200-day moving average price of $8.75. Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $10.90. The company’s market cap is $288.52 million.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The business had revenue of $4.91 million during the quarter. Equities analysts predict that Neos Therapeutics will post ($3.11) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Neos Therapeutics, Inc. (NEOS) a $20.00 Price Target” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/01/cantor-fitzgerald-analysts-give-neos-therapeutics-inc-neos-a-20-00-price-target.html.

A number of institutional investors and hedge funds have recently made changes to their positions in NEOS. Stonepine Capital Management LLC bought a new position in Neos Therapeutics during the second quarter worth about $4,125,000. Essex Investment Management Co. LLC bought a new position in Neos Therapeutics during the second quarter worth about $1,400,000. Russell Investments Group Ltd. lifted its stake in Neos Therapeutics by 167.9% during the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock worth $1,971,000 after purchasing an additional 169,237 shares during the period. Columbus Circle Investors lifted its stake in Neos Therapeutics by 156.2% during the second quarter. Columbus Circle Investors now owns 272,934 shares of the company’s stock worth $1,992,000 after purchasing an additional 166,414 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Neos Therapeutics by 25.7% during the second quarter. Vanguard Group Inc. now owns 740,160 shares of the company’s stock worth $5,403,000 after purchasing an additional 151,166 shares during the period. Hedge funds and other institutional investors own 44.32% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.